XIFIN LIS 8
Now with more digital pathology options for a streamlined and flexible workflow
Plus New Laboratory Information System Capabilities That Save Time and Increase Throughput for High-Complexity, High-Volume Labs
Introducing the latest release of award-winning XIFIN LIS, a scalable, SaaS-based laboratory information system (LIS) that offers multi-specialty workflows, new interfacing tools, document storage and the ability to integrate digital pathology solutions. XIFIN LIS 8 delivers more scalability and interoperability and an optimized user experience, and demonstrates XIFIN’s continued investment in improving operational, clinical, and financial outcomes for diagnostic providers.
As COVID-19 swept across the U.S. over the past year, laboratories have faced extraordinary challenges standing up new tests and processing fluctuating testing volumes that for some labs peaked at over 700% of baseline volumes. According to a recent US Laboratory Satisfaction Survey conducted by XIFIN, 16% of respondents indicated their LIS doesn’t scale well and 32% indicate their LIS scales for near-term growth but has a ceiling.
Shifting consumer demands and COVID-drive needs have accelerated the adoption of digital pathology and telehealth — spotlighting the need for flexible SaaS solutions that can respond to dynamic shifts in how labs intake tests and process results. The need for increased testing capabilities, and the technology to support it, is becoming even more apparent with the prevalence of troubling COVID-19 variants.
XIFIN LIS 8 provides enhanced capabilities that help labs grow and adapt to recent and future needs, including:
Request your copy of the upcoming State of US Laboratory Information Systems research report.
"With XIFIN’s LIS offerings we will be able to scale our operations for future growth and integrate our lab information with our TissueCypher® computational pathology workflow, creating a complete end-to-end solution. By implementing the Concentriq® digital pathology platform from Proscia and integrating it with the XIFIN lab information system, we will be able to rapidly scale our precision medicine business model and accelerate adoption of the TissueCypher Barrett's Esophagus Assay, the world's first precision medicine test to predict the risk of future development of esophageal cancer in patients with Barrett's esophagus. The innovative end-to-end solution from XIFIN and Proscia will also streamline collaboration amongst our multidisciplinary team of cancer biologists, artificial intelligence scientists, and pathologists to accelerate the development of the novel AI-driven precision medicine solutions in our pipeline."
Co-founder and CSO
Hear more about the Cernostics case study in the upcoming webinar, "One Lab's Journey - Transforming Diagnostic Service Delivery Through an Integrated Digital Pathology Ecosystem"
September 22 at 12PM ET / 9AM PT